Submit Deal

AEXERNA THERAPEUTICS

Summary

aexeRNA Therapeutics is developing mRNA therapeutics utilizing its proprietary next generation programmable and highly potent Lipid Nanoparticle nucleic acid delivery system.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 812 M

Avg. Deal Size£ 812 M

Market Context

Senior Management

Drew Weissman
Co-Founder
Manuel Carrasco
Co-Founder
Mikell Paige
Co-Founder

Sort

08 Nov 2023|United States|Biotechnology

Target: AEXERNA THERAPEUTICS

Bidder: BIONTECH

3 Service Providers

2 Target | 1 Bidder

7 Dealmakers

5 Target | 2 Bidder

£ 812 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy